Protein Summary
Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate glucose 6-phosphate. It contributes to the catabolism of dietary galactose and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. Both UDP-sugar interconversions are important in the synthesis of glycoproteins and glycolipids. This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only o ...more
- ENST00000374497
- ENSP00000363621
- ENSG00000117308
- ENST00000617979
- ENSP00000483375
- SDR1E1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
histone modification site profile | 0.84 | ||
transcription factor | 0.77 | ||
protein domain | 0.73 | ||
transcription factor binding site profile | 0.7 | ||
interacting protein | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 406.78 (req: < 5)
Gene RIFs: 12 (req: <= 3)
Antibodies: 280 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 406.78 (req: >= 5)
Gene RIFs: 12 (req: > 3)
Antibodies: 280 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1
Protein Sequence and Structure
Residue Counts
Protein Sequence
ProtVista Viewer
Expression Data (0 Tissues)
Related Tools

TIGA scores and ranks GWAS discovered associations according to the quantity and quality of the evidence supporting the association.

GENEVA (GENe Expression Variance Analysis) allows you to identify RNA-sequencing datasets from the Gene Expression Omnibus (GEO) that contain conditions modulating a gene or a gene signature.

GlyGen is a data integration and dissemination project for carbohydrate and glycoconjugate related data.

ARCHS4 provides access to gene-function predictions based on RNA-seq co-expression, and gene expression levels across cell and tissues.
Approved Drugs (1)
Active Ligands (1)
Protein-Protein Interactions (119)
POP5
Family: Enzyme
Novelty: 0.02459167
p_int: 0.998209564
p_ni: 0.00179027
p_wrong: 1.66e-7
Data Source: BioPlex
FAM24B
Novelty: 1.04675689
p_int: 0.996756401
p_ni: 0.003242547
p_wrong: 0.000001052
Data Source: BioPlex
Nearest Tclin Targets (2)
Upstream (2)
1 – 2 of 2
Pathways (17)
Reactome (7)
KEGG (3)
PathwayCommons (6)
UniProt (1)
Click on a row in the table to change the structure displayed.
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
Reactome | Defective GALE can cause Epimerase-deficiency galactosemia (EDG) | ||||
Reactome | Disease | ||||
Reactome | Diseases associated with glycosylation precursor biosynthesis | ||||
Reactome | Diseases of glycosylation | ||||
Reactome | Galactose catabolism | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Defective GALE can cause Epimerase-deficiency galactosemia (EDG) | ||||
Disease | ||||
Diseases associated with glycosylation precursor biosynthesis | ||||
Diseases of glycosylation | ||||
Galactose catabolism | ||||
Viral Interactions (0)
Gene Ontology Terms (6)
Functions (4)
Components (1)
Processes (1)
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Physical Interaction (IPI) | IntAct | |||
Inferred from Physical Interaction (IPI) | UniProtKB | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-EC | |||
Disease Associations ()
GWAS Traits (5)
Items per page:
1 – 5 of 5
GWAS Trait | EFO ID | Study Count | SNP Count | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|---|---|
reticulocyte count | 6 | 4 | 6 | 92.4 | |||||
eosinophil count | 3 | 3 | 3 | 91.9 | |||||
reticulocyte measurement | 3 | 2 | 3 | 90.5 | |||||
eosinophil percentage of leukocytes | 2 | 2 | 2 | 85.5 | |||||
eosinophil percentage of granulocytes | 1 | 1 | 1 | 35 | |||||
Items per page:
1 – 5 of 5
GWAS Trait | EFO ID | Beta Count | Odds Ratio | Evidence (Mean Rank Score) | Provenance | ||
---|---|---|---|---|---|---|---|
reticulocyte count | 6 | 92.4 | |||||
eosinophil count | 3 | 91.9 | |||||
reticulocyte measurement | 3 | 90.5 | |||||
eosinophil percentage of leukocytes | 2 | 85.5 | |||||
eosinophil percentage of granulocytes | 1 | 35 | |||||
Find similar targets by:
IDG Resources
Orthologs (15)
1 – 5 of 15
Species | Name | Source ID | Gene ID | OMA | EggNOG | Inparanoid | ||
---|---|---|---|---|---|---|---|---|
Chimp | UDP-galactose-4-epimerase | VGNC:11436 | 456623 | |||||
Macaque | UDP-galactose-4-epimerase | 710553 | ||||||
Mouse | MGI:1921496 | 74246 | ||||||
Rat | RGD:621493 | 114860 | ||||||
Dog | UDP-galactose-4-epimerase | VGNC:41080 | 100855555 | |||||
Species | Name | OMA | EggNOG | Inparanoid | ||
---|---|---|---|---|---|---|
Chimp | UDP-galactose-4-epimerase | |||||
Macaque | UDP-galactose-4-epimerase | |||||
Mouse | ||||||
Rat | ||||||
Dog | UDP-galactose-4-epimerase | |||||
Publication Statistics
PubMed Score 406.78
PubMed score by year
PubTator Score 115.16
PubTator score by year
Related Publications
Text Mined References (37)
GeneRif Annotations (12)
Items per page:
0 of 0
PMID | Year | Title |
---|